iPSC-Derived Cell Therapies Summit to Feature Discussion on Trailblazing Therapies for Immuno-Oncology-Panelists Include Exacis Biotherapeutics CEO

Dr. Gregory Fiore, Co-Founder, President and CEO of Exacis Biotherapeutics will participate in an industry leader fireside chat focused on “Taking a Look at the Current Learnings from iPSC-Derived Cell Therapies and Determining Future Outlook and Developments” at the 2^nd iPSC-Derived Cell Therapies Summit. Dr. Fiore will join an expert panel that will reflect on current learnings from therapy development to drive focus and motivation while highlighting the demands of the future. Discussion will include validating iPSCs as starting material for immuno-oncology and regenerative medicine therapies to drive further investment and efforts in the space.

“These cutting-edge therapies are the future of medicine” said Dr. Fiore. “I am excited to be part of this forum where industry leaders can share their expertise on what is happening with iPSC-derived cell therapies and where the industry is heading.”

The discussion will take place at 9 am ET on Tuesday, December 6, 2022.

Held December 6-7 in Boston, the 2^nd iPSC-Derived Cell Therapies Summit will focus on the creation of safe and effective iPSC-derived therapies for immuno-oncology and regenerative medicine. Participants will include iPSC drug developers working from discovery to CMC and will cover topics such as optimizing directed differentiation, enhancing expansion, advancing next-generation gene engineering approaches to improve safety, and defining the critical quality attributes to develop best-in-class iPSC-based therapies.

Exacis is a development stage immuno-oncology company focused on harnessing the human immune system to cure cancer by engineering next generation off-the-shelf NK and T cell therapies aimed at hematologic malignancies and solid tumors. Exacis was founded in 2020 with an exclusive global license to a broad suite of patents covering the use of mRNA based cell reprogramming and gene editing technologies for use in generating engineered NK and T cells for oncology applications.

Exacis’ approach avoids the use of DNA and viruses and instead uses a proprietary mRNA based technology. Exacis uses the technology to generate iPSCs and to edit their genome to create stealthed, performance enhanced allogeneic NK and T cell products, termed ExaNK™, ExaCAR-NK™ and ExaCAR-T™ cells.

T and NK cells are types of human immune cells that are able to recognize and destroy cancer cells and can be modified through genetic engineering to target and kill specific tumors.

Contact Exacis Biotherapeutics for further information and media: 

Exacis Biotherapeutics 

info@exacis.com